Clinical Trials Browser

Recruiting × Leukemia × midostaurin × Clear all

NCT06313437 2025-03-27

Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute